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Introduction: Diversity in cognition among apolipoprotein E (APOE) ε4 homozygotes
can range from early-onset Alzheimer’s disease (AD) to a lifetimewith no symptoms.
Methods: We evaluated a phenotypic extreme polygenic risk score (PRS) for AD
between cognitively healthyAPOE ε4homozygotes aged≥75years (n=213) andearly-
onset APOE ε4 homozygote AD cases aged ≤65 years (n = 223) as an explanation for
this diversity.
Results: The PRS for AD was significantly higher in APOE ε4 homozygote AD cases
compared to older cognitively healthy APOE ε4/ε4 controls (odds ratio [OR] 8.39; con-
fidence interval [CI] 2.0–35.2;P= .003). The difference in the samePRSbetweenAPOE
ε3/ε3 extremes was not as significant (OR 3.13; CI 0.98–9.92; P= .053) despite similar
numbers and power. There was no statistical difference in an educational attainment
PRS between these age extreme case-controls.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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Discussion: A PRS for AD contributes to modified cognitive expression of the APOE
ε4/ε4 genotype at phenotypic extremes of risk.
KEYWORDS
Alzheimer’s disease, Alzheimer’s disease dementia, apolipoprotein E, dementia resilience, genetic
modifiers, polygenic risk score
1 BACKGROUND
Alzheimer’s disease (AD) has a strong underlying genetic
component.1–3 However, in the majority of individuals with non-
Mendelian AD, no single gene mutation can be identified as causative,
with studies showing that AD is either an oligogenic or a polygenic
disease.4–6 The apolipoprotein E (APOE) ε4 allele has been identified
as the single biggest risk factor.7 The presence of APOE ε4 in the
heterozygous form confers a 2- to 3-fold increase in the odds of devel-
oping AD and in the homozygous form this confers up to a 14.9-fold
increase compared to the most common APOE genotype of ε3/ε3.8
Moreover, the presence of APOE ε4 accelerates the age of onset (AOO)
of AD, with themean AOObeing 84.3 years in non-carriers as opposed
to 68.4 years in those who are APOE ε4/ε4.9
Despite the high risk for AD, it has been recognized that there is
considerable phenotypic diversity among APOE ε4 homozygotes, rang-
ing from early-onset AD to a lifetime with no symptoms of cogni-
tive impairment.10–13 The reasons for this phenotypic diversity remain
largely unexplained. Due to this variability in risk, APOE ε4 genotype,
even in the homozygous state, has not demonstrated reliable utility
for individual prediction of AD susceptibility or AOO of AD.14,15 As
there is a large polygenic component to AD, genetic factors beyond
the APOE ε4 genotype may account for some of this modification in
risk. Using data from large AD-related genome-wide association stud-
ies (GWAS),16–18 polygenic risk scores (PRS) have been developed and
used to predict risk for AD.6,16,19–24 However, to our knowledge, no
studyhas beendesigned specifically to examine themodificationof risk
by a PRS for AD between phenotypic extremes of the APOE ε4/ε4 risk
spectrum. In this study, we investigate the role of an ADPRS, excluding
the APOE region, as a potential modifier of risk between the two phe-
notypic extreme ends of the APOE ε4/ε4 AD risk spectrum, comparing
the PRS between cognitively healthy older APOE ε4/ε4 controls with-
out AD and APOE ε4/ε4 early-onset clinically diagnosed AD cases.
2 METHODS
2.1 Participants
To compare aPRS forADbetween the phenotypic extremeof theAPOE
ε4/ε4 risk spectrum, we obtained young onset AD cases and cogni-
tively healthy older controls of European origin with APOE ε4/ε4 geno-
type from various cohorts. This included genotype data from APOE
ε4/ε4 AD cases with AOO ≤ 65 years (n= 223) and cognitively healthy
older APOE ε4/ε4 controls without a diagnosis of AD aged ≥ 75 years
(n= 213).
Cases came from the Alzheimer’s Disease Genetics Consortium
(ADGC) (n = 200) and The Australian Imaging, Biomarkers & Lifestyle
Flagship Study of Ageing (AIBL; n = 23). Diagnosis of probable AD
in the cases was made using the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) or the National Institute of Neurological
and Communicative Disorders and Stroke– Alzheimer’s Disease and
Related Disorders Association (NINDS-ADRDA) criteria or based on
detailed clinical assessment in individual cohorts. Further details of
these cohorts can be found in supporting information, the National
Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site
(NIAGADS; https://www.niagads.org/home), Kunkle et al.,18 and Ellis
et al.25
Cognitively healthy olderAPOE ε4/ε4 controlswithout a diagnosis of
AD were from the Aspirin in Reducing Events in the Elderly (ASPREE)
study26 (n = 175), AIBL (n = 12), and ADGC (n = 26). ASPREE par-
ticipants in this group had no clinical diagnosis of AD as determined
by a multidisciplinary adjudicating committee and passed a test of
global cognition (ModifiedMini-Mental State Examination [3MS] score
of > 77) at enrolment. Control participants from AIBL had no clini-
cal AD or mild cognitive impairment also determined by a multidis-
ciplinary adjudicating committee. Controls with no reported clinical
AD were also included from ADGC, in which individual cohorts used
specifically designed cognitive screening criteria to determine “non
demented” status (https://www.niagads.org/home). Any ADGC sample
thatwas included in IGAP stage 1 or IGAP stage 2 in theGWASby Lam-
bert et al.16 was excluded, to remove overlap with current PRS anal-
ysis. Demographic characteristics of cases and controls are shown in
Table 1.
Matched numbers ofAPOE ε3/ε3AD cases (n= 223) with AOO≤ 65
years andAPOE ε3/ε3cognitivelyhealthy controls (n=213)withoutAD
aged ≥ 75 years were also included to compare the effect of the PRS
in APOE ε3/ε3 extremes. Cases and controls for the APOE ε3/ε3 com-
parison were European ancestry participants, sourced from ADGC. As
APOE ε3 is the most common genotype in the general population, this
genotype was chosen for the comparison analysis.27
This study was approved by the Royal Melbourne Hospital Ethics
Committee (HREC/17/MH/444) for use of pre-collected data. Eth-
ical approval for the individual cohort participants was provided
by their respective institutional ethics boards. All participants had
provided DNA samples to the respective cohorts with consent for
genotyping and data use. All patient data was anonymized prior
to analysis. The reporting of this study follows the Strengthening
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the Reporting of Observational studies in Epidemiology (STROBE)
guidelines for case-control studies (https://www.strobe-statement.
org/index.php?id= strobe-home).
2.2 Generating AD PRS in phenotypic extremes
A phenotypic extremes study design was used to select cases and con-
trols for this study.28,29 Study design is depicted in Figure 1.
Detailed information on genotyping and quality control (QC) steps
is included in supporting information. Tomitigate the amount of techni-
cal variability introduced by combining samples frommultiple cohorts,
only samples that passed QC filters based on sex, relatedness, and
European ancestry were included. Principal component analysis (PCA)
on the top 10 principal components (PC) was done in each cohort to
exclude outliers. Variants with call rates < 95% and those likely to
have been improperly genotyped or imputed based on a test of Hardy-
Weinberg equilibrium were excluded. QC was repeated after merging
the cohorts and PCA was again performed to control for population
stratification.
PRS is calculated as a single score generated by aggregating the
effects of genetic variants across the genome relevant for that par-
ticular trait.30 As there is no published PRS available for a pheno-
typic and age extremeADdataset of homozygous APOE genotypes, we
undertook a clumping and thresholding method (described in support-
ing information) to generate a PRS in our age and phenotypic extreme
APOE ε4/ε4 and APOE ε3/ε3 samples.
Clumping and thresholding is a common method used to compute
PRS. Single nucleotide polymorphisms (SNPs) are first selected from
GWAS summary statistics. The clumping step ensures that only vari-
ants that are weakly correlated with one another are retained in a pre-
specified window of the genome (in this case 1000 kilobase windows).
Then the thresholding step is used to remove variants with a P-value
larger than a chosen level of significance (in this study, SNPs from the
IGAP GWAS were threshold at r2> 0.1). Only the most significant P-
value threshold was used to select the SNPs that form the PRS.
RESEARCH INCONTEXT
1. Systematic review: Despite the high risk for Alzheimer’s
disease (AD), there is considerable diversity in cognition
among apolipoprotein E (APOE) ε4 homozygotes, ranging
from early-onset AD to a lifetimewith no dementia. Liter-
ature review (PubMed) revealed that the reasons for this
phenotypic diversity remain largely unexplained. In this
study, we investigated the effect of a polygenic risk score
(PRS) in this modification.
2. Interpretation: Using an extremes phenotype study
model, we demonstrate that a PRS for AD contributes to
modified cognitive expression of the APOE ε4/ε4 geno-
type.
3. Future directions: This study demonstrates an effective
framework for investigation of risk modifiers in AD. A
similar model can be used to investigate other AD risk
modifiers. Conducting genome-wide association studies
using this framework, with larger participant numbers,
may lead to discovery of novel risk-modifying loci. Inclu-
sion of AD riskmodifiers alongwithAPOE genotypingwill
aid in more accurate AD risk prediction.
The phenotypic extreme APOE ε4/ε4 as well as APOE ε3/ε3 partic-
ipants (total cases n = 446; total controls n = 426) were combined
to generate the PRS. To calculate PRS without APOE, variants within
750 kilobases of the start or end of the APOE gene (chr19:44659011-
46162650, hg19) were excluded. Effect sizes for the weighting of the
SNPsused for thePRSgenerationwas from theGWASanalysis by Lam-
bert et al.16 Themore recentGWASbyKunkle et al. was not used as the
ADGCsamples in this studyoverlapwith theirGWASstudy.18 The soft-
ware PRSice-2 was used to calculate and optimize PRS using clump-
ing and thresholding.31,32 The steps followed in the PRS generation are
shown in Figure 1.













Total numbers 223 213 223 213
Numbers by cohort:
ASPREE 0 175 0 0
AIBL 23 12 0 0
ADGC 200 26 223 213
Median AOO/AAA
(range) in years
62.5 (47–65) 80.5 (75–91) 57 (34–64) 83 (76–97)
Female sex 53.8% 52.6% 53.4% 62.9%
Abbreviations:AAA, age at assessment;AD,Alzheimer’s disease;ADGC,Alzheimer’sDiseaseGeneticsConsortium;AIBL, TheAustralian Imaging, Biomarkers
& Lifestyle Flagship Study of Ageing; AOO, age of onset; ASPREE, Aspirin in Reducing Events in the Elderly; APOE, apolipoprotein E.
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F IGURE 1 Flow-chart detailing the study design. AAA, Age at assessment; ADGC, Alzheimer’s Disease Genetics Consortium; AIBL, The
Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing; AOO, age of onset; ASPREE, Aspirin in Reducing Events in the Elderly study;
IGAP, International Genomics of Alzheimer’s Project; OR, odds ratio; PC, principal components; PRS, polygenic risk score; QC, quality control.
Summary statistics for IGAP stage 1 and 2 samples derived from Lambert et al.16 Principal component analysis (PCA) was done using first ten PCs
based on the 1000Genomes reference population
2.3 Statistical analysis
Using the PRS thus generated, themeans of PRS distributions between
the age extreme APOE ε4/ε4 cases and APOE ε4/ε4 controls were first
analyzed using the statistical test analysis of covariance (with 10 PCs
as covariates) andpost hoc t test. Thiswas done to check that therewas
significant difference in PRS between the cases and controls in each
group before calculating odds ratios (OR). Subsequently, OR were cal-
culated between the lowest and highest 20% of PRS (OR_20%) by per-
forming logistic regressions betweenPRS quintile andAD status, in the
APOE ε4/ε4 case-controls, and also in theAPOE ε3/ε3 case-controls. OR
were also calculated per standard deviation increase in PRS (OR_Stnd)
by performing logistic regressions with Z-standardized PRS as the pre-
dictor and AD status as the response. Level of significance was set at
P< .05.
To verify if the variation in PRS was influenced by differences in
other AD-related risk factors in the APOE ε4/ε4 phenotypic extremes,
we intended to check for differences in educational attainment
between the cases and controls. Of the various modifiable risk factors,
low level of education is the only trait to exhibit consistent association
with AD.33 Large GWAS studies have shown that genetically predicted
education correlates with actual level of education and that high edu-
cation attainment PRS is protective against AD.34 As level of education
was not available as a variable across the different cohorts included
in our study, we calculated an education attainment PRS based on the
GWAS study by Lee et al.35 as a proxy for level of education in theAPOE
ε4/ε4 extremes. To generate the education attainment PRS, we applied
clumping and thresholding to the Lee et al. GWASusing the samemeth-
ods as described above for AD. The statistical package R (version 3.6.2)
was used for statistical analysis and figures.36
3 RESULTS
Out of a total of 5,295,512 SNPs that passed QC in the combined
APOE ε4/ε4 andAPOE ε3/ε3 age-extreme samples, after excluding SNPs
at a minor allele frequency (MAF) < 0.05 and clumping, 33,780 SNPs
remained. These SNPs were then subjected to P-value thresholding.
Figure 2 shows the results of the clumping and thresholding process.
The r2 explained by PRS was calculated at IGAP GWAS P-values from
5 × 10–08 to 1. There were 21 SNPs that fell in the most significant
threshold, with the corresponding P-value bracket being P< 5× 10–08.
ThisP-value happened to correspond to theP-value universally used to
select the most significant SNPs in GWAS studies, that is, at genome-
wide significance level. Details of these SNPs are provided in Table S1
in supporting information.
The difference in means between the extreme cases and controls
was significant in both the APOE ε4/ε4 case-controls (P< .001) and the
APOE ε3/ε3 case-controls (P< .001) showing that the participants with
AD have a significantly higher PRS compared to controls (Figure 3).
TheOR_20% inAPOE ε4/ε4 extremeswas 8.39 (confidence interval [CI]
2.0–35.2; P = .003), indicating a significant depletion of high risk PRS
SNPs in the cognitively healthy older controlswithAPOE ε4/ε4.Wealso
calculated the OR per standard deviation for the entire distribution of
the APOE ε4/ε4 extreme cases and controls. OR_Stnd was 1.58 (CI 1.1–
2.3; P= .013; Figure 4).
As APOE ε3/ε3 is the most common genotype in the general popula-
tion and considered the population reference, analysis in participants
with this genotype was used as a comparison to determine whether
there is a modifying effect of the PRS in APOE ε4-negative phenotypic
extremes. OR between the highest and lowest 20th percentile, that is,
OR_20% was 3.13 (CI 0.98–9.92; P = .053), showing a relatively lower
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F IGURE 2 Line plot depicting the thresholding of single nucleotide polymorphisms. Each dot represents a different thresholding window. Best
threshold in this case was at P< 5× 10–08
F IGURE 3 Density plot showing the difference in polygenic risk score distribution in cases and controls in the apolipoprotein E (APOE) ε4/ε4
extremes and APOE ε3/ε3 extremes
influence of thismodifyingPRS in theAPOE ε3/ε3phenotypic extremes,
as opposed to the APOE ε4/ε4 phenotypic extremes at the two extreme
quintile ends of the PRS distribution. OR_Stnd was 1.36 (CI 0.99–1.85;
P= .054; Figure 4).
To clarify if the risk modification conferred by the PRS in APOE
ε4/ε4s may have been influenced by a difference in education attain-
ment, we checked for differences in genetically determined education
attainment between the APOE ε4/ε4 cases and controls as well as the
APOE ε3/ε3 cases and controls. The education attainment PRS was
more polygenic with 24,502 SNPs falling under the most significant
threshold of P= .3. The education attainment PRSwas not significantly
different between the APOE ε4/ε4 extreme cases and controls with
OR_20% 0.52 (CI 0.17–1.60; P = .26) and OR_Stnd 0.83 (CI 0.6–1.16;
P = .28), indicating that the influence of genetically determined edu-
cation attainment was not confounding. Similarly, there was no statis-
tically significant difference in the education attainment PRS between
the APOE ε3/ε3 extreme cases and controls with OR_20% being 3.12
(CI 0.98–9.92; P= .05) and OR_Stnd being 0.70 (CI 0.42–1.14; P= .15;
Figure 4).
4 DISCUSSION
In this study, we compared a PRS between phenotypic extremes of the
APOE ε4/ε4 spectrum and demonstrated that the PRS was significantly
higher in APOE ε4 homozygotes diagnosed with AD earlier in life,
compared to APOE ε4 homozygotes who remained unaffected by AD
to an advanced age. The PRS was also compared between a matched
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F IGURE 4 Odds ratio of risk-modifying polygenic risk score (PRS) as well as education attainment PRS in apolipoprotein E (APOE) ε4/ε4
extremes and APOE ε3/ε3 extremes. CI, confidence interval; OR, odds ratio
number of APOE ε3/ε3 young onset cases and unaffected controls, but
was not as significant as the APOE ε4/ε4 case-controls. Our findings
illustrate how genetic risk modification in AD can be driven by com-
mon AD-associated variants beyond the APOE locus, and that this risk
modification may partially explain the phenotypic diversity among
APOE ε4 homozygotes.
Our extreme phenotyping study design increased the ability to
detect this PRS modifying effect. Extreme phenotyping is known to
increase statistical power andvariant effect sizes, enabling better iden-
tification of SNPs strongly associatedwith a trait.28 ForAD, an extreme
phenotyping study translates to comparing risk factors between those
at the highest risk, that is, AD cases with APOE ε4/ε4 and onset ≤ 65
years, with those who are most resilient to AD, being those with APOE
ε4/ε4 genotype, aged≥ 75 years and no AD.37 Here, we have identified
a PRS that modifies risk between the phenotypic extreme ends of the
APOE ε4/ε4 spectrum. This finding has important implications for the
potential risk stratification of this high-risk genotype.
The loci that yielded the 21 SNPs forming risk-modifying PRS in
this study have all been previously described in AD GWAS with no
new loci found in this study. This shows that the currently known non-
APOE loci still play an important role in risk modification. Thus far,
up to 44 loci have been reported to be associated with AD in large
GWAS.5,16–18,38,39 However, it remains unresolved if AD is oligogenic,
with risk determined by a smaller number of SNPs compared to other
common diseases such as coronary artery disease and cancer; or is
polygenic with similar genetic architecture to these diseases.5,6 The
present analysis has demonstrated that a detectable risk-modifying
effect in APOE ε4/ε4 extremes is driven by a relatively small number of
SNPs in the common frequency range. Our study showed that a lower
burden of some non-APOE SNPs in APOE ε4 homozygotes could buffer
disease risk and delay AD onset to≥ 75 years.
An improved understanding of the modifying effect of PRS on the
APOE ε4/ε4 genotype could assist in increasing the accuracy of risk
prediction for AD. Similar risk modification by PRS has been shown
recently in the context of autosomal dominant adult-onset mono-
genic conditions, in which polygenic factors have been shown to mod-
ify the penetrance of clinically significant monogenic variants.40 Such
improved risk stratification is useful in identifying people at increased
risk or at decreased risk despite their APOE ε4/ε4 genotype.
In the clinical setting, the APOE genotype has posed several chal-
lenges. The variability in ADphenotype despite the high risk hasmeant
that testing for the APOE ε4 genotype has been discouraged by the
American College of Medical Genetics and Genomics, especially in the
predictive context in asymptomatic individuals.41 Addition of PRS to
the APOE ε4/ε4 genotyping increases the predictive value of such test-
ing and may allow the incorporation of APOE ε4/ε4 testing in the clinic,
where more accurate prediction of the chances of developing AD is
considered useful. It will also becomemore relevant as effective thera-
pies for AD are developed.
Although phenotypic variability may also be true for the heterozy-
gous APOE ε4 genotype, given that the elevated OR of developing late-
onset AD in APOE ε4 homozygotes (up to 14.9) is markedly different
fromhaving oneAPOE ε4allele (up to4), the factors thatmodify the risk
in APOE ε4 heterozygotes will be much broader, possibly with smaller
effect sizes compared to those modifying APOE ε4/ε4 risk.8 The pre-
dictive value for AD by inclusion of a modifying PRS in addition to
APOE ε4/ε4 genotyping would be significantly higher than the predic-
tive value of adding a modifying PRS to APOE ε4 heterozygotes. The
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APOE ε4/ε4 modifying PRS, especially in the extremes of phenotypes
as described in this study, is therefore valuable in selecting appropri-
ate participants for study of risk and resilience and will also contribute
toward a better understanding of the genetic and non-genetic factors
underpinning AD and how they interact.
We were able to successfully incorporate an extreme pheno-
type design to identify the modifying PRS by using well-phenotyped,
resilient older controls in our study. Resilient controls are defined as
those that do not develop a particular condition, despite being at a high
risk for developing it. As the average age of onset of AD in APOE ε4
homozygotes is 68.4 years,9 those who have the APOE ε4/ε4 genotype
and are aged at least 75 years or older without major cognitive impair-
ments, can be considered to be harboring factors that buffer the devel-
opmentofAD, despite their high risk. In somepreviousADcase-control
studies, participants too young be considered controls for AD have
been used.42–44 This confounds the ability to accurately determine
risk-modifying factors, as many of the controls may go on to develop
ADwhenolder. In the current study,wehadaccess towell-phenotyped,
advanced aged elderly control cohorts of APOE ε4/ε4 participants, who
fit the definition of resilience for AD. Using appropriately phenotyped
extreme cases and controls strengthens the ability to find meaningful
modifying factors.
Although many lifestyle and environmental factors can also play a
part in themodification of risk of AD, no single environmental/lifestyle
risk factor has been shown to be strongly associated with AD.33 A
recent study analyzing causal associations between various modifi-
able risk factors and the AD phenome, using PRS and Mendelian ran-
domization, showed only genetically determined education attainment
was causally associated with decreased risk of AD, delayed AOO, and
increased cortical surface area and thickness.45 Studies have shown
that the effect of education is particularly prominent in early years and
that the effect of education is difficult to separate out fromoverall cog-
nitive ability.46,47 In a large GWAS study, Lee et al. were able to show
that the SNPs associatedwith education attainment explained a signif-
icant proportion of educational variance.35 Wewere also able to show
that the difference in theAPOE ε4/ε4modifying PRSwas not influenced
by the difference in education attainment PRS.
4.1 Limitations
The main constraint in following an approach of extreme phenotyping
for AD is the reduced number of participants available for the study.
Although our results are encouraging, the number of participants in
our study was still relatively small. It is likely that the current PRS
used in our study only captures a fraction of the genetic variation or
divergence that may drive phenotypic expression between APOE ε4/ε4
extremes. The smaller size has limited the power of our study to iden-
tify novel SNPs from the existing GWAS data. A substantially larger
number of participants would be required to perform an independent
GWAS using the extreme phenotype approach or to investigate the
role of rarer variants of strong effect. Larger independent studies are
also needed to validate the results from our study. However, ascertain-
ing individuals at either end of the APOE ε4/ε4 risk spectrum is par-
ticularly challenging given that the population genotype frequency of
APOE ε4/ε4 in Europeans is only 2%. This necessitated combining sam-
ples from multiple cohorts in our analysis, which may have introduced
some technical variation between cohorts and issues related to popu-
lation stratification. We have tried to account for this by various QC
checks and PCA, but acknowledge that despite this, there may be dis-
similarities between the cohorts.
Moreover, risk prediction for AD remains complicated due to the
complex genetic–environmental interactions and likely involvement of
epigenetic mechanisms. We acknowledge that despite having small
effect sizes individually, in combination, many lifestyle/environmental
factorsmay play a larger part inmodifying AD risk and this effect could
not be accounted for in the present study.48
There may also be other rare, high-effect genetic variants influenc-
ing risk or resilience that have not been captured by our analysis. In
addition, our analysis does not cover genomic structural variants such
as deletions, duplications, and short tandem repeats that may con-
tribute toward modification of AD risk. It is also to be noted that this
PRS is not transferable to the non-White population as our study pop-
ulation was predominantly of EuropeanWhite ethnicity.
5 CONCLUSIONS
In conclusion, our study demonstrates that a PRS for AD modifies the
phenotypic expression of AD between extreme ends of the APOE ε4/ε4
risk spectrum. This suggests that common genetic variants beyond the
APOE locus contribute to risk modification in AD, yet it is likely that far
more genetic and non-genetic factors contribute, beyond those cap-
tured by the PRS. Further studies are required to better understand
the underlying biology of genetic risk modifiers in AD. Although not
available in all our study cohorts, positron emission tomography or
cerebrospinal fluid biomarkers of amyloid beta (Aβ) should be explored
in the resilient controls in future studies to investigate if the non-
amyloidogenic loci represented by the 21 SNPs described here counter
the effects of Aβ in the brain.
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